

Review

Neglected Tropical Diseases of Oceania: Review of Their Prevalence, Distribution, and Opportunities for Control

Kevin Kline^{1,2}, James S. McCarthy³, Mark Pearson⁴, Alex Loukas⁴, Peter J. Hotez^{1,2*}

1 Departments of Pediatrics and Molecular Virology & Microbiology, and National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America, **2** Sabin Vaccine Institute and Texas Children's Hospital-Baylor College of Medicine Center for Vaccine Development, Houston, Texas, United States of America, **3** Clinical Tropical Medicine Laboratory, Queensland Institute of Medical Research, University of Queensland, Brisbane, Australia, **4** Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Cairns, Queensland, Australia

Abstract: Among Oceania's population of 35 million people, the greatest number living in poverty currently live in Papua New Guinea (PNG), Fiji, Vanuatu, and the Solomon Islands. These impoverished populations are at high risk for selected NTDs, including *Necator americanus* hookworm infection, strongyloidiasis, lymphatic filariasis (LF), balantidiasis, yaws, trachoma, leprosy, and scabies, in addition to outbreaks of dengue and other arboviral infections including Japanese encephalitis virus infection. PNG stands out for having the largest number of cases and highest prevalence for most of these NTDs. However, Australia's Aboriginal population also suffers from a range of significant NTDs. Through the Pacific Programme to Eliminate Lymphatic Filariasis, enormous strides have been made in eliminating LF in Oceania through programs of mass drug administration (MDA), although LF remains widespread in PNG. There are opportunities to scale up MDA for PNG's major NTDs, which could be accomplished through an integrated package that combines albendazole, ivermectin, diethylcarbamazine, and azithromycin, in a program of national control. Australia's Aboriginal population may benefit from appropriately integrated MDA into primary health care systems. Several emerging viral NTDs remain important threats to the region.

Introduction

The neglected tropical diseases (NTDs) represent the most common infections of the world's poorest people, a group sometimes known as "the bottom billion" [1,2]. These tropical infections trap people in poverty through their adverse effects on worker productivity, pregnancy outcomes, and child cognition and development [1,2]. Recently, the World Health Organization (WHO) developed a list of 17 NTDs [3], with an expanded list of these conditions on the website of *PLOS Neglected Tropical Diseases* [4]. Since 2008, efforts have been made to review and describe the differences in the etiologies, prevalence, and disease burden of the major NTDs according to their regional distribution [5–12]. In this respect, the prevalence and distribution of the NTDs in the Americas [5–7], Europe [8], sub-Saharan Africa [9], China and East Asia [10], India and South Asia [11], Central Asia [12], and the Middle East and North Africa [13] have been previously reviewed. Here we summarize current knowledge on the prevalence and distribution of the NTDs in the region known as Oceania, which includes Australia, New Zealand, Melanesia, and the Polynesian and Micronesian islands of the Pacific. This review was conducted using the online database PubMed from 1997 to 2012 with the Medical Subject Headings, the specific diseases listed in the WHO's first report on NTDs, and the list from *PLOS*

Neglected Tropical Diseases [3,4], as well as the geographic regions and countries of Oceania. Reference lists of identified articles and reviews were also manually searched, as were databases from the WHO (<http://www.who.int>), including the *Weekly Epidemiological Record*.

Poverty in Oceania

Approximately 35 million people live in Oceania, a region of tropical and sub-tropical islands in the South Pacific Ocean (Figure 1). Almost two-thirds of the population (22.3 million) lives on the continent of Australia, followed in descending order by Papua New Guinea (6.8 million), New Zealand (4.4 million), Fiji (0.9 million), and the Solomon Islands (0.5 million) (Table 1). In all, of the dozens of island nations that comprise Oceania, more than 99% live in eight nations including those listed above, together with French Polynesia, New Caledonia, and Vanuatu. Despite their proximity to one another, the nations of Oceania represent a diverse array of economies. Australia and New Zealand each rank near the top of the United Nations human development indices (HDI, 2nd and 5th, respectively) [14], whereas more than one-third of the population of Papua New Guinea (PNG) live below the World Bank poverty figure of US\$1.25 per day [15]. PNG has an HDI of 153, placing it near the bottom of the global HDIs and is one of only four non-sub-Saharan countries (the others being Afghanistan, Haiti, and Yemen) with HDIs below 150 [14]. Fiji, Vanuatu, and the Solomon Islands also have HDIs of 100 or lower [14]. However, extremely impoverished indigenous groups are also found within the two wealthiest countries in the region, Australia and New Zealand. For instance, Aboriginal Australians, numbering nearly half a million, earn average incomes amounting to 62% of non-indigenous residents [16]. Within Australia, indigenous Australians reside in greatest numbers in New South Wales and Queensland,

Citation: Kline K, McCarthy JS, Pearson M, Loukas A, Hotez PJ (2013) Neglected Tropical Diseases of Oceania: Review of Their Prevalence, Distribution, and Opportunities for Control. *PLoS Negl Trop Dis* 7(1): e1755. doi:10.1371/journal.pntd.0001755

Editor: Simon Brooker, London School of Hygiene & Tropical Medicine, United Kingdom

Published: January 31, 2013

Copyright: © 2013 Kline et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: No specific funding was received for this work.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hotez@bcm.edu




Figure 1. Map of West Pacific Islands. <http://www.worldofmaps.net/en/oceania/map-pacific/map-west-pacific-islands.htm>, accessed May 20, 2012. doi:10.1371/journal.pntd.0001755.g001

although the Northern Territory has the highest percentage of Aboriginal people [17].

Throughout the world's low- and middle-income countries, and even among wealthy countries, the NTDs disproportionately affect people living in poverty, but especially those in extreme poverty [5–13]. Here we provide an overview of the major NTDs affecting people living in poverty in Oceania, with an emphasis on the eight nations with populations that exceed 200,000 and comprise more than 99% of the number of people living in this region.

Helminth Infections

Helminth infections may represent the most prevalent NTDs in Oceania, led by hookworm and lymphatic filariasis (LF; Tables 2 and 3), although significant numbers of cases of ascariasis, trichuriasis, strongyloidiasis, and hymenolepiasis are also present.

Soil-Transmitted Helminth Infections

Hookworm infection is possibly the most prevalent NTD in Oceania, with an estimated 5.5 million cases, comprising roughly

Table 1. The Countries and Population of Oceania and the Percentage Living in Poverty.

Nation	Total Population	Percentage of Population Living below US\$1.25 per Day	Percentage of Incidence of Poverty ^a or Population below the Threshold for Relative Poverty ^b	Percentage of Population below 50% Median Income
Australia	22.3 million	N/A	N/A	N/A
Papua New Guinea	6.8 million	37.5 [15]	N/A	N/A
New Zealand	4.4 million	N/A	N/A	11 [123]
Fiji	860,000	31.0 [15]	35 [124]	N/A
Solomon Islands	538,000	N/A	22.7 [125]	N/A
French Polynesia	270,764	N/A	27.6 [126]	N/A
New Caledonia	254,000	N/A	N/A	17 [127]
Vanuatu	239,000	9.2 [128]	N/A	N/A

^aFiji, Solomon Islands.

^bFrench Polynesia.

doi:10.1371/journal.pntd.0001755.t001

Table 2. Major Helminth Infections in Oceania.

Disease ^a	Estimated Number of Cases in Oceania	Percentage of Global Disease Burden	Refs
Hookworm infection	5.5 million	1%	[18,129]
Lymphatic Filariasis	2.7 million	2%	[34,130]
Trichuriasis	1.2 million	<1%	[18,129]
Ascariasis	1.2 million	<1%	[18,129]

^aNumbers for the hookworm infection, trichuriasis, and ascariasis were derived by multiplying the current population of each nation as reported in Table 1 by the percentage of people infected as reported in reference [18].
doi:10.1371/journal.pntd.0001755.t002

1% of the world's cases of hookworm infection [18]. Most of Oceania's hookworm cases are concentrated in PNG, where according to some estimates three-quarters of the population is infected, followed by Fiji, the Solomon Islands, and Vanuatu [18]. *Necator americanus* is the predominant hookworm species in PNG, comprising 100% of the hookworms in some areas [19,20] (Supplemental Table 1 in Text S1) It is not known whether *Ancylostoma duodenale* is also present in PNG, but during the Australian Hookworm Campaign of 1919–1924, PNG was also studied, and *N. americanus* was found to be virtually the only hookworm detected [21]. In contrast, both *N. americanus* and *A. duodenale* may have been present historically in Australia among both white and Aboriginal communities. Today, hookworm is found almost exclusively among Aboriginal Australians in Western Australia and the Northern Territory, where *A. duodenale* is believed to be the sole species [21]. During the 1990s, isolated Aboriginal populations in northwest Australia exhibited hookworm prevalence rates that exceeded 75% (with high rates of hookworm anemia) [22], but no recent published data are available. However, it is likely that mass drug administration (MDA), although provided inconsistently, has reduced the hookworm prevalence among selected communities [23]. A unique eosinophilic enteritis syndrome caused by the dog hookworm, *Ancylostoma caninum*, has also been reported from north Queensland, and elsewhere in Australia, although it is not considered a significant public health problem [24].

Among the other soil-transmitted helminth nematode infections, ascariasis and trichuriasis are much less common in Oceania. However, trichuriasis appears to be a common geohelminth in Fiji, accounting for almost one-half of the number of cases in Oceania, while large numbers of cases also appear in the Solomon Islands and Vanuatu [18]. PNG accounts for much of the ascariasis in Oceania [25], followed by Fiji, the Solomon Islands, and Vanuatu

[18]. Strongyloidiasis is an important soil-transmitted helminth infection in Oceania, although no overall prevalence data are available. Among Aboriginal Australian populations, the high rates of *Strongyloides stercoralis* infection may partly reflect a high incidence of human T-cell lymphotropic virus type 1 (HTLV-1) infections, which predisposes to this parasite. Prevalence rates of *S. stercoralis* infection as high as 60% have been reported [26]. A high mortality from *S. stercoralis* and HTLV-1 co-infections can result because of *Strongyloides* hyperinfection [27]. In a study of *Strongyloides* hyperinfection in central Australia among Australian Aboriginals, 77% were found to be HTLV-1 positive [28]. In PNG, *S. stercoralis* infection also occurs [26], as well as a unique form of strongyloidiasis caused by *S. fuelleborni kellyi* [25]. This form of the infection can be vertically transmitted, and has been associated with swollen belly syndrome in the Gulf and Madang provinces [25]. In one study, 27% of children tested positive for *Strongyloides*, with 81% of these children under the age of one [25]. Strongyloides-infected populations in both Australia and PNG may therefore benefit from MDA programs using ivermectin [26]. Outside of PNG, *S. stercoralis* infection has recently been described in medical volunteers in the Solomon Islands [29]. Sporadic cases of human *Trichostrongylus* infections have also been reported [30–32].

Hymenolepis nana infection has been reported as a common soil-transmitted cestodiasis among Aboriginal communities in Australia and PNG [23,33], although the overall prevalence is not known. In Australia's Northern Territory, MDA with albendazole was found to be ineffective at reducing the prevalence of this infection [23].

Lymphatic Filariasis (LF)

Next to hookworm and possibly strongyloidiasis, LF is likely to be the most prevalent helminthic NTD in Oceania. Although LF is

Table 3. Geographic Distribution of the Major Helminthic NTDs in Oceania.

Disease ^a	Country of Largest Prevalence (# of Cases)	Country of Second Largest Prevalence (# of Cases)	Country of Third Largest Prevalence (# of Cases)	Country of Fourth Largest Prevalence (# of Cases)	Refs
Hookworm	Papua New Guinea (4.9 million)	Fiji (318,000)	Solomon Islands (192,000)	Vanuatu (88,000)	[18]
Trichuriasis	Fiji (541,000)	Solomon Islands (338,000)	Papua New Guinea (204,000)	Vanuatu (150,000)	[18]
Ascariasis	Papua New Guinea (748,000)	Fiji (215,000)	Solomon Islands (135,000)	Vanuatu (59,000)	[18]
Lymphatic filariasis	Papua New Guinea (2.7 million)				[34]

^aNumbers for the hookworm infection, trichuriasis, and ascariasis were derived by multiplying the current population of each nation as reported in Table 1 by the percentage of people infected as reported in reference [18].
doi:10.1371/journal.pntd.0001755.t003

found throughout Oceania, PNG is the only nation with a published national prevalence estimate [34]. In 1997 it was estimated that approximately 2.7 million people were infected [34], accounting for more than 2% of the global disease burden. Since then, MDA has been implemented with diethylcarbamazine citrate (DEC) plus albendazole [35]. On Lihir Island, MDA in conjunction with vector control led to a 75% reduction in the seroprevalence of microfilarial antigenemia [36,37] and evidence of reduced transmission [38]. Despite these measures, the WHO reported in 2010 that, of the 5.6 million people in PNG who would benefit from empirical chemotherapy for LF, only 6.3% had been covered nationally [39].

Throughout most of Oceania, LF elimination efforts through MDA are underway through the auspices of the Pacific Programme to Eliminate Lymphatic Filariasis (PacELF) [40]. MDA has now ceased in Vanuatu because the prevalence has dropped below the 1% threshold. Ongoing post-MDA surveillance will be required to certify elimination efforts in this country [40]. On Ouvéa Island, New Caledonia, a survey indicated that approximately one-third of the population was antigenemic prior to launching their PacELF program [41]. As of 2010, mapping of LF is complete in New Caledonia, but no MDA program has been implemented [39]. Fiji and French Polynesia currently have active MDA programs underway with 100% coverage [36]. On Fiji's Kadavi Island, DEC has reduced the percent testing positive for microfilaremia by 90% [42]. In PNG, PacELF has not yet been implemented at a national level. The remaining countries—Australia, New Zealand, and Solomon Islands—are considered non-endemic [36]. Of interest, the Solomon Islands achieved elimination largely through a program of vector control rather than MDA [43].

Zoonotic Helminth Infections

Two emerging helminth zoonoses, cystic echinococcosis (hydatid disease) and cysticercosis, are of concern. While several eradication programs have been implemented on the mainland of Australia, *Echinococcus granulosus* remains widespread among sheep and macropods [44,45]. In Tasmania, following a successful eradication program, only one echinococcosis case of mainland Australian origin has been reported since 1974 [46]. Although echinococcosis has been declared eliminated in New Zealand, reports of hydatid disease presentations have occurred in Auckland, likely through importation [46,47]. Cysticercosis is not endemic in Australia, but it has occurred in recent immigrants and Australians traveling to endemic regions [48,49]. In PNG, indigenous and West Papuan refugees living along the border were found to have asymptomatic *Taenia solium* infections, but more comprehensive studies are needed to recognize the true prevalence of infection [50]. *Trichinella pseudospiralis* infections have been isolated from humans in Tasmania [51].

Protozoan Infections

The major intestinal protozoan infections in Oceania are amebiasis, balantidiasis, cryptosporidiosis, and giardiasis (Supplemental Table 5). In Australia, these infections can disproportionately affect Aboriginal populations. However, no overall prevalence estimates are available. Among urban Australians, an analysis of seroprevalence of men who have sex with men (MSM) indicated that HIV+ MSM have a higher seroprevalence of *Entamoeba* sp. infection than HIV− MSM [52,53]. It is uncertain whether this represents infection with the pathogenic species *Entamoeba histolytica* or the saprophyte *Entamoeba dispar*. In New

Caledonia, *E. histolytica* was found among hospitalized patients with hepatic abscesses [54]. Epidemic foci of *Balantidium coli* infection have been reported from swine-producing areas of PNG, and an outbreak of balantidiasis was described after a typhoon on Truk resulted in contamination of ground and surface water with pig feces [55]. Giardiasis is also common among Aboriginal Australians and presumably other populations in Oceania [22]. Albendazole used for deworming these populations may also have had some activity against *Giardia* [56,57]. Among non-Aboriginal communities, exposure to this pathogen has been identified in waterborne outbreaks, and is believed to be common among children in daycare settings [58–60]. In New Zealand, *Giardia* parasites were found in some people presenting with acute gastrointestinal illness [61]. Chagas disease is not endemic in any of the nations in the Oceania region. However, immigration of over 80,000 immigrants from Latin America to Australia in 2006 is likely to have resulted in the importation of 1,000 or more cases [62]. When combining the permanent arrivals from Argentina, Brazil, Chile, El Salvador, and Uruguay, as well as the resident population of Latin American immigrants from Columbia and Peru, the potential number of infected individuals in this group has been estimated to be 16 per 1,000 in Australia [63].

Bacterial and Fungal NTDs

The major bacterial NTDs include the treponematoses, yaws, and congenital syphilis; intracellular bacterial infections including active trachoma, leprosy, Buruli ulcer, bartonellosis, bovine tuberculosis (TB), and brucellosis; and leptospirosis and cholera (Supplemental Tables 2–4, 6). Mycetoma is a fungal NTD in the region.

Treponematoses

Yaws has not been eliminated from Oceania despite its susceptibility to MDA with azithromycin, or azithromycin used together with DEC in programs of PacELF [64,65] (Supplemental Table 6). While great strides have been made in eliminating yaws, this chronic infection remains endemic in PNG, the Solomon Islands, and Vanuatu, although advanced cases are rare [66]. Infections occur among schoolchildren in PNG, including a high proportion of cases in the secondary stage (46%) [67], while an unspecified number of cases have been serologically detected in the Solomon Islands and elsewhere [68,69]. Studies on school children from the island of Tanna in Vanuatu have recently confirmed a resurgence of yaws [70]. As part of WHO's elimination program for congenital syphilis, PNG, the Solomon Islands, and Fiji have reported surveillance data on this infection, with PNG exhibiting the highest prevalence [71]. A prior WHO report combined seven studies of maternal syphilis seroprevalence from 1997 to 2003 for Vanuatu. Studies of syphilis among pregnant women were also performed in New Caledonia with seroprevalence between 7% and 12.4% [72].

Active Trachoma, Leprosy, and Other Intracellular Bacterial NTDs

Trachoma infections occur in Australia, PNG, Fiji, Vanuatu, and the Solomon Islands (Supplemental Table 2). The most recent released data from the WHO in 2003 indicated the greatest number of active trachoma cases were in PNG (16,289), followed by Australia (8,800), Fiji (1,865), and the Solomon Islands (1,403) [73]. Additional data indicated that the prevalence of active trachoma in Fiji, the Solomon Islands, and Vanuatu are similar

(22%–23%) [74]. Aboriginal Australians living in remote communities also suffer from high prevalence of trachoma [75]. The SAFE (surgery, antibiotics, facial cleanliness, and environmental control) program has been implemented among Aboriginal Australians communities, with some reductions in overall prevalence [76].

The prevalence of leprosy is again highest in PNG, with 281 reported new cases in 2010 in addition to an estimated 580 existing cases [77]. Among Aboriginal Australians in the early 1950s, the incidence of diagnosis of leprosy was 270 per 100,000, but had fallen to 4/100,000 in the Northern Territory by 1997 [78]. This decrease was attributed to widespread use of the BCG vaccine in Aboriginal populations since 1958 [78]. Buruli ulcer, another mycobacterial infection, is endemic in some specific locations in Southeastern Australia and Queensland, with focal outbreaks being reported [79,80]. Bartonellosis caused by *Bartonella henselae* has been detected in blood donors from Australia and New Zealand, as well as in children with hepatic abscesses in New Caledonia [81–84]. Bovine TB is present New Zealand, but it represents a small proportion of the overall TB incidence in Oceania [85,86]. There were also cases of bovine TB originating in PNG that were detected in Australia [86]. Brucellosis is reportable in Australia, with 32 cases documented in 2009 [87].

Leptospirosis

Leptospirosis is endemic in Oceania, with both sporadic cases and outbreaks being reported. In Australia, there has been a significant increase in the incidence of leptospirosis over the past decade, with the heaviest occupational burden among banana farmers and dairy workers [88]. In 2009, Australia reported 149 cases of leptospirosis nationally, with over 75% of the cases occurring in Queensland [87]. In New Zealand, 81 cases of leptospirosis were reported in 2010, with an elevated incidence in Ruapehu, the West Coast District, and Hawke's Bay [89,90]. In New Caledonia, an outbreak of leptospirosis occurred during heavy rainfalls and flooding attributed to La Nina [91], while American Samoa was found to have a high prevalence of the disease [92]. Previously in Fiji, Vanuatu, and French Polynesia, *Leptospira icterohemorrhagiae* was identified as the dominant species [93,94].

Cholera

Cholera outbreaks have been noted in several nations of Oceania. In 2009, an outbreak occurred in PNG, eventually reaching 8,997 cases by the end of 2010, with the highest incidence in the Madang Province [95,96]. In addition, an outbreak was reported from a resort in Fiji [97]. In Australia, four cases, all imported were reported in 2009.

Arboviral Infections

The major arboviral infections in Oceania are the flavivirus infections caused by dengue, Japanese encephalitis (JE), and Murray Valley encephalitis (MVE), as well as mosquito-transmitted alphavirus infections, Ross River virus (RRV) and Barmah Forest virus (BFV).

Overall, the incidence of dengue is underreported in Oceania. In Australia, dengue infection and associated mortality were first identified in Charters Towers in northern Queensland in 1897 [98]. There have been reports of dengue in Fiji, French Polynesia, New Caledonia, the Solomon Islands, and Vanuatu prior to 1950 [99]. In 2010, the Western Pacific Region of the WHO (WPRO) reported national incidence data for dengue in

Australia, Fiji, French Polynesia, New Caledonia, New Zealand, and Vanuatu (Supplemental Table 4) [100]. French Polynesia, New Caledonia, Vanuatu, and Australia accounted for more than 90% of the reported cases within the Western Pacific subregion [100]. In Australia, North Queensland reports the greatest number of cases [100], which included an outbreak during the 2008–2009 wet season [101]. Dengue is not endemic in New Zealand, and in 2010 all 51 reported cases in New Zealand were of foreign origin, with Vanuatu accounting for 12% of those cases [87,100]. In addition to WPRO surveillance, a seroprevalence study indicated that dengue has also emerged in the Solomon Islands [102]. The overall epidemiology of dengue is perhaps least understood in PNG, although evidence for the infection has been found in adults and children with febrile illness [103].

Within Oceania, JE and MVE are found primarily in Australia and PNG. JE emerged during the 1990s in PNG and in the Torres Strait of Australia [104]. The reports of JE in the Torres Strait islands may have resulted from movement of migratory birds or wind-blown mosquitoes from PNG [105]. The JE isolates from PNG and Torres Strait share >99% sequence identity [106]. In Australia, MVE is endemic in north and southeastern Australia, with four cases reported 2009 [87,107], while in PNG MVE was identified in mosquito isolates, but no human seroprevalence data are available [106].

In Australia, RRV infection has been reported periodically, but outbreaks have become more intense and frequent [108]. In 2009, 4,786 cases were reported in Australia, with nearly half in Queensland [87]. In PNG, no national prevalence data have been compiled, but in the Southern Highlands Province antibody prevalence for RRV was 59% [109]. After an apparent disappearance in the years following a 1979–1980 outbreak, RRV has reemerged in Fiji [110]. BFV is unique to Australia, and is distributed throughout the continent with the highest incidence in Queensland [111]. In 2008, the national incidence of BFV was found to have increased 34% over the mean rate of the previous 5 years [111]. Within Australia, RRV and BFV account for most of the reported arbovirus disease notifications [101].

Ectoparasitic Infections

Scabies is a major endemic ectoparasitic infection among Aboriginal Australians and in other Oceanic nations. In Australia, pre-treatment prevalence levels exceeded 30% among indigenous children in some communities [112,113], with high rates of secondary infections of streptococcal pyoderma [112–114]. MDA treatment with ivermectin in a village in PNG was found to reduce scabies prevalence by two-thirds to 26% [115]. In the Solomon Islands, scabies prevalence among children was reduced with ivermectin treatment to 0.7% [116]. In two studies undertaken in Fiji, the burden of scabies in schoolchildren was between 18.5% and 32% [117,118]. A study in Vanuatu demonstrated increased efficacy of ivermectin over benzyl benzoate in treating childhood scabies [119]. Myiasis has also been reported in New Zealand, acquired both in the country and internationally [120].

Discussion

Several important NTD trends have emerged in the Oceania region.

1. *MDA*. Proof of concept for achieving success in MDA in Oceania has been obtained through the PacELF with high

Learning Points

- The efficacy of the Pacific Programme to Eliminate Lymphatic Filariasis (PacELF) has been demonstrated in Oceania, but enhanced efforts are still required in Papua New Guinea and New Caledonia.
- While proof of concept for NTD management in Oceania was shown by PacELF, novel MDA programs need to be crafted, especially in Papua New Guinea and Aboriginal Australia, in order to target specific NTDs indigenous to neglected populations in these regions, including hookworm, strongyloidiasis, and other soil-transmitted helminthiasis, yaws, trachoma, and scabies.
- While the impact of emerging arboviral infections, including dengue, Japanese encephalitis, and Ross River virus infection, is still not well understood, these diseases could also emerge as important NTDs in the coming decade.

levels of LF treatment coverage in Fiji, French Polynesia, and New Caledonia, and the possible elimination of LF in Vanuatu [40]. The Solomon Islands has previously eliminated LF through vector control [43]. As such successes have not yet extended to PNG, it remains the most endemic in Oceania [36,40]. A concerted effort in PNG for LF elimination in the coming years would be consistent with efforts by the Global Programme to Eliminate LF's to eliminate this disease as a public health problem globally by 2020 [40,121]; there is an urgency to ensure that the government of PNG has the adequate human capital and technical support as well as sufficient funding to expand MDA and elimination efforts. Currently, there are no comprehensive post-MDA surveil-

Key Articles in the Field

1. King SE, Mascie-Taylor CG (2004) Strongyloides fuelleborni kellyi and other intestinal helminths in children from Papua New Guinea: associations with nutritional status and socioeconomic factors. *PNG Med J* 47: 181–191.
2. Weil GJ, Kastens W, Susapu M, Laney SJ, et al (2008) The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on Bancroftian filariasis in Papua New Guinea. *PLoS Negl Trop Dis* 2: e344. doi:10.1371/journal.pntd.0000344
3. Andrews RM, Kearns T, Connors C, Parker C, et al. (2009) A regional initiative to reduce skin infections amongst Aboriginal children living in remote communities of the Northern Territory, Australia. *PLoS Negl Trop Dis* 3: e554. doi:10.1371/journal.pntd.0000554
4. Van den Hurk AF, Craig SB, Tulsiana SM, Jansen CC (2010) Emerging tropical diseases in Australia. Part 4. Mosquitoborne diseases. *Ann Trop Med Parasitol* 104: 623–640.
5. Mitja O, Hays R, Ipai A, Penias M, Paru R, Fagaho D, et al. (2012) Single dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. *Lancet* 379: 342–347.

lance programs in place for any LF-endemic country in the region. The development and implementation of surveillance plans for all countries will be important to monitor areas of persistent or re-emerging LF [40]. Additional targets for MDA in Oceania could include soil-transmitted helminth infections, which could be linked to LF elimination efforts through the addition of albendazole to DEC, as well as yaws elimination through the addition of azithromycin to DEC [64,65]. The recent finding by Mitja et al. that single-dose azithromycin is as effective as benzathine benzyl penicillin for the treatment of yaws in PNG is an important breakthrough on that front [64]. There are opportunities to scale up these options, especially in PNG [64].

2. *PNG*. More than any other nation in Oceania, PNG stands out with respect to having the largest number of cases and high prevalence of several key NTDs, including *N. americanus* hookworm infection, strongyloidiasis, hymenolepiasis, LF, balantidiasis, yaws, trachoma, leprosy, and possibly scabies and dengue and other arboviral infections, as well as outbreaks of cholera [18,25,33,34,55,64,73,77,103,115]. PNG could benefit enormously from a national control program of integrated MDA that simultaneously targets many of these NTDs using the drugs albendazole, ivermectin, DEC, and azithromycin. Therefore, there are opportunities to collect the safety data needed to determine the suitability of combining these medicines in an integrated MDA package, together with financial support for implementation linked to operational research.
3. *Aboriginal populations in Australia*. Australia's Aboriginal population also suffers from disproportionately high rates of NTDs, including strongyloidiasis, leprosy, and scabies, and possibly hookworm infection [26,73,112,113]. There may be opportunities for integrating MDA packages as outlined above for PNG into programs of primary care for Australia's Aboriginal populations.
4. *Arboviral infections*. The impact of arboviral infections, especially emerging dengue and RRV in PNG, is still not well understood [106]. Dengue, JE, and RRV could emerge as important NTD pathogens in Oceania in the coming decade. Malaria is endemic in regions of PNG, the Solomon Islands, and Vanuatu. In the Solomon Islands, malaria vector control was responsible for a substantial reduction of LF [122]. Current malaria programs implemented by the Pacific Malaria Initiative Support Centre (PacMISC) in Vanuatu and the Solomon Islands as well as the Global Fund in PNG are promising tools for reducing the burden of several mosquito-borne diseases, particularly in PNG, where *Anopheles* transmit both malaria and LF. Integration of monitoring and evaluation M&E in these programs and in non-endemic nations will provide assistance in controlling the rising threat of arboviral pathogens in the future.

In summary, tremendous strides have been made in controlling and eliminating selected NTDs in Oceania, but mostly through PacELF. There is an urgent need to extend these successes to all of the major NTDs throughout the region but especially in PNG and among Aboriginal Australians.

Supporting Information

Text S1 Supporting file containing Supplemental Tables 1–7. (DOC)

References

1. Hotez PJ (2010) A plan to defeat neglected tropical diseases. *Sci Am* 302: 90–94.
2. Hotez PJ, Fenwick A, Savioli L, Molyneux DH (2009) Rescuing the “bottom billion” through neglected tropical disease control. *Lancet* 373: 1570–1574.
3. World Health Organization (2010) Working to overcome the global impact of neglected tropical diseases: First WHO report on neglected tropical diseases. 172 p.
4. PLoS Neglected Tropical Diseases (2011) PLoS Neglected Tropical Diseases journal scope. Available: <http://www.plosntds.org/static/scope.action>. Accessed January 8, 2012.
5. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, et al. (2008) The neglected tropical diseases of Latin America and the Caribbean: review of estimated disease burden and distribution and a roadmap for control and elimination. *PLoS Negl Trop Dis* 2: e300. doi:10.1371/journal.pntd.0000300
6. Hotez PJ (2008) Neglected infections of poverty in the United States of America. *PLoS Negl Trop Dis* 2: e256. doi:10.1371/journal.pntd.0000256
7. Hotez PJ (2010) Neglected infections of poverty among the indigenous peoples of the Arctic. *PLoS Negl Trop Dis* 4: e606. doi:10.1371/journal.pntd.0000606
8. Hotez PJ, Gurwith M (2011) Europe’s neglected infections of poverty. *Int J Infect Dis* 15: e611–e619.
9. Hotez PJ, Kamath A (2009) Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution and disease burden. *PLoS Negl Trop Dis* 3: e412. doi:10.1371/journal.pntd.0000412
10. Hotez PJ, Ehrenberg J (2010) Escalating the global fight against neglected tropical diseases through interventions in the Asia Pacific Region. *Adv Parasitol* 7C2: 31–53.
11. Lobo DP, Velayudhan R, Chatterjee P, Kohl H, Hotez PJ (2011) The neglected tropical diseases of India and South Asia: review of their prevalence, distribution, and control or elimination. *PLoS Negl Trop Dis* 5: e1222. doi:10.1371/journal.pntd.0001222
12. Hotez PJ, Alibek K (2011) Central Asia’s hidden burden of neglected tropical diseases. *PLoS Negl Trop Dis* 5: e1224. doi:10.1371/journal.pntd.0001224
13. Hotez PJ, Savioli L, Fenwick A (2012) Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. *PLoS Negl Trop Dis* 6: e1475. doi:10.1371/journal.pntd.0001475
14. United Nations Development Programme (UNDP) Human development index. United Nations. Available: <http://hdr.undp.org/en/statistics/hdi/>. Accessed 30 Jan. 2012.
15. The World Bank. Human development indicators. Available: <http://data.worldbank.org/country>. Accessed 5 Jan. 2013.
16. Australian Human Rights Commission (2009) Social justice report 2008. Available: http://www.hrec.gov.au/social_justice/sj_report/sjreport08/index.html. Accessed 30 Jan. 2012.
17. Australian Bureau of Statistics (2006) Population distribution, Aboriginal and Torres Strait Islander Australians, 2006. Available: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/4705.0>. Accessed 30 Jan. 2012.
18. de Silva NR, Brooker S, Hotez PJ, Montresor A, et al. (2003) Soil-transmitted helminth infections: Updating the global picture. *Trends Parasitol* 19: 547–551.
19. Pritchard DI, Quinnell RJ, Slater AF, McKean PG, et al. (1990) Epidemiology and immunology of *Necator americanus* infection in a community in Papua New Guinea: humoral responses to excretory-secretory and cuticular collagen antigens. *Parasitology* 100: 317–326.
20. Quinnell RJ, Griffin J, Nowell MA, Raiko A, et al. (2001) Predisposition to hookworm infection in Papua New Guinea. *Trans R Soc Trop Med Hyg* 95: 139–142.
21. Procić P, Luke RA. (1995) The changing epidemiology of human hookworm infection in Australia. *Med J Aust* 162: 150–154.
22. Hopkins RM, Gracey MS, Hobbs RP, Spargo RM (1997) The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north-west Australia. *Med J Aust* 166: 241–244.
23. Thompson RCA, Reynoldson JA, Garrow SC, McCarthy JS, et al. (2001) Towards the eradication of hookworm in an isolated Australian community. *Lancet* 357: 770–771.
24. Procić P, Croese J (1996) Human enteric infection with *Ancylostoma caninum*: hookworms reappraised in the light of a “new” zoonosis. *Acta Trop* 62: 23–44.
25. King SE, Mascie-Taylor CG (2004) *Strongyloides fuelleborni* kellyi and other intestinal helminthes in children from Papua New Guinea: associations with nutritional status and socioeconomic factors. *PNG Med J* 47: 181–191.
26. Shield JM, Page W (2008) Effective diagnostic tests and anthelmintic treatment for *Strongyloides stercoralis* make community control feasible. *PNG Med J* 51(3–4): 105–119.
27. Igra-Siegmán Y, Kapila R, Sen P, Kaminski ZC, et al. (1981) Syndrome of hyperinfection with *Strongyloides stercoralis*. *Rev Infect Dis* 1981 3: 397–407.
28. Einsiedel L, Fernandes L (2008) *Strongyloides stercoralis*: a cause of morbidity and mortality for indigenous people in Central Australia. *Internal Medicine Journal* 38: 697–703.
29. Pattison DA (2008) *Strongyloidiasis* in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI). *The Medical Journal of Australia* 189(4): 203–206.
30. Boreham RE, McCowan MJ, Ryan AE, Allworth AM, et al. (1995) Human trichostrongyliasis in Queensland. *Pathology* 27: 182–185.
31. Ralph A, O’Sullivan MVN, Sangster NC, Walker JC (2006) Abdominal pain and eosinophilia in suburban goat keepers. *Medical Journal of Australia* 9: 467–469.
32. Wall EC, Bhatnagar N, Watson Julie, Doherty T (2011) An unusual case of hyper eosinophilia and abdominal pain: an outbreak of trichostrongylus imported from New Zealand. *J Travel Med* 18(1): 59–60.
33. Owen IL (2005) Parasitic zoonoses in Papua New Guinea. *J Helminthol* 79(1): 1–14.
34. Michael E (1997) Global mapping of lymphatic filariasis. *Parasitol Today* 13(12): 472–476.
35. Weil GJ, Kastens W, Susapu M, Laney SJ, et al. (2008) The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on Bancroftian filariasis in Papua New Guinea. *PLoS Negl Trop Dis* 2: e344. doi:10.1371/journal.pntd.0000344
36. WHO (2005) Global Programme to Eliminate Lymphatic Filariasis: annual report on lymphatic filariasis 2003. World Health Organization.
37. Mitjà O, Paru R, Hays R, Griffin L, Laban N, et al. (2011) The impact of a filariasis control program on Lihir Island, Papua New Guinea. *PLoS Negl Trop Dis* 5(8): e1286. doi:10.1371/journal.pntd.0001286
38. Hii J, Brockarie MJ, Flew S, Genton B et al. (2000) The epidemiology and control of lymphatic filariasis on Lihir Island, New Ireland Province. *The Papua New Guinea Medical Journal* 43(3–4): 188–195.
39. World Health Organization. Preventive chemotherapy databank. Available: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/index.html. Accessed 5 Jan. 2013.
40. World Health Organization (2008) Report of the ninth workshop for Pacific lymphatic filariasis programme managers. Available: http://www2.wpro.who.int/NR/rdonlyres/68DCB443-20CD-4E7E-96F5-0FB73092123C/0/MR_NinthWorkshopPacificLymphaticFilariasisProgramme.pdf. Accessed 30 Jan. 2012.
41. Monchy D (1999) Survey of lymphatic filariasis on Ouvéa Island in New Caledonia. *Médecine Tropicale: Revue Francophone De Pathologie Et De Santé Publique Tropicales* 59:2: 146–150.
42. Mataika JU (1998) Efficacy of five annual single doses of diethylcarbamazine for treatment of lymphatic filariasis in Fiji. *Bull World Health Organ* 76(6): 575–579.
43. World Health Organization - Regional Office for the Western Pacific (1998) Fifty years of WHO in the Western Pacific region, 1948–1998: report of the regional director to the regional committee for the Western Pacific. Forty-ninth session. World Health Organization. pp. 188–192.
44. Jenkins DJ (2006) *Echinococcus granulosus* in Australia, widespread and doing well! *Parasitol Int* 55 Suppl: S203–S206.
45. Jenkins DJ, Power K (1996) Human hydatidosis in New South Wales and the Australian Capital Territory, 1987–1992. *Med J Aust* 164: 18–21.
46. Craig PS, Larrieu E (2006) Control of cystic echinococcosis/hydatidosis: 1863–2002. *Adv Parasitol* 61: 443–508.
47. Koea JB (2008) Cystic lesions of the liver: 6 years of surgical management in New Zealand. *N Z Med J* 121: 61–69.
48. Hughes AJ, Biggs BA (2002) Parasitic worms of the central nervous system: an Australian perspective. *Internal Medicine Journal* 32: 541–553.
49. Hellard ME, Street AC, Johnson PDR, Popovic EA, et al. (1998) Detection of an aberrant motile larval form in the brain of a patient with neurocysticercosis. *Clinical Infectious Diseases* 27: 391–393.
50. Wandra T, Ito A, Yamaki H, Suroso T, et al. (2003) *Taenia solium* cysticercosis, Irian Jaya, Indonesia. *Emerging Infectious Disease* 9(7): 884–885.
51. Pozio E, Owen IL, La Rosa G, Sacchi L, et al. (1999) *Trichinella papuae* n.sp. (Nematoda), a new non-encapsulated species from domestic and sylvatic swine of Papua New Guinea. *Int J Parasitol* 29: 1825–1839.
52. Stark D (2007) Prevalence of enteric protozoa in human immunodeficiency virus (HIV)-positive and HIV-negative men who have sex with men from Sydney, Australia. *Am J Trop Med Hyg* 76(3): 549–552.
53. James R (2010) Short report: seroprevalence of *Entamoeba histolytica* infection among men who have sex with men in Sydney, Australia. *Am J Trop Med Hyg* 83(4): 914–916.
54. Guittet V (2004) Hepatic abscesses in childhood: retrospective study about 33 cases observed in New-Caledonia between 1985 and 2003. *Archives De Pédiatrie : Organe Officiel De La Société Française De Pédiatrie* 11.9: 1046–1053.
55. Schuster, FL Ramirez-Avila, L (2008) Current world status of *Balantidium coli*. *Clin Microbiol Rev* 21: 626–638.
56. Reynoldson, James A (1997) Failure of pyrantel in treatment of human hookworm infections (*Ancylostoma Duodenale*) in the Kimberley Region of North West Australia. *Acta Tropica* 68: 301–312.
57. Reynoldson JA (1998) Efficacy of albendazole against *Giardia* and hookworm in a remote Aboriginal Community in the North of Western Australia. *Acta Tropica* 71: 27–44.
58. Sinclair MI, Hellard ME, Wolfe R, Mitakakis TZ, Leder K, et al. (2005) Pathogens causing community gastroenteritis in Australia. *Journal of Gastroenterology and Hepatology* 20(11): 1685–1690.

59. Ferson MJ, Stringfellow S, McPhie K, McIver CJ, et al. (1997) Longitudinal study of rotavirus infection in child-care centres. *J Paediatr Child Health* 33(2): 157–160.
60. Dale K, Martyn K, Sinclair M, Hall R, et al. (2010) Reported waterborne outbreaks of gastrointestinal disease in Australia are predominantly associated with recreational exposure. *Australian and New Zealand Journal of Public Health* 34(5): 527–530.
61. Lake R (2009) Acute gastrointestinal illness in New Zealand: information from a survey of community and hospital laboratories. *N Z Med J* 122(1307): 48–54.
62. Schmunis GA, Yadon ZE (2010) Chagas disease: a Latin American health problem becoming a world health problem. *Acta Trop* 115(1–2): 14–21.
63. Schmunis GA (2007) Epidemiology of Chagas disease in non endemic countries: the role of international migration. *Memórias Do Instituto Oswaldo Cruz* 102: 75–86.
64. Mitjå O, Hays R, Ipai A, Penias M, et al. (2012) Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. *Lancet* 379(9813): 342–347. Epub 2012 Jan 11.
65. World Health Organization Region for Southeast Asia New Delhi (2006) Fifth Meeting of National Lymphatic Filariasis Programme Managers of the WHO South-East Asia Region. 5–7 July 2006. 1–27.
66. Capuano C, Ozaki M (2011) Yaws in the Western Pacific region: a review of the literature. *Journal of Tropical Medicine* 2011: 1–15.
67. Mitjå O, Hays R, Lehgei F, Laban N, et al. (2011) Challenges in recognition and diagnosis of yaws in children in Papua New Guinea. *Am J Trop Med Hyg* 85: 113–116.
68. Guerrier G, Marcon S, Garnotel L, Deltour R, et al. (2011) Yaws in Polynesia's Wallis and Fatuna Islands: a seroprevalence survey. *N Z Med J* 124: 29–31.
69. Lucas RE, Faoagali JL (1999) The serological status of Solomon Island blood donors. *Southeast Asian J Trop Med Public Health* 30: 542–545.
70. Fegan D, Glennon MJ, Thami Y, Pakoa G (2010) Resurgence of yaws in Tanna, Vanuatu: time for a new approach? *Trop Doct* 40: 68–69.
71. WHO (2012) Global HIV/AIDS response epidemic update and health sector progress towards universal access progress report 2011. World Health Organization, UNAIDS, UNICEF.WEB. 1 Feb 2012. pp. 176–178.
72. Ménard D (2001) Toxoplasmosis, rubella, syphilis, hepatitis B and HIV infection in women being followed for pregnancy in a population on the east coast of New Caledonia. *Bull Soc Pathol Exot* 94: 403–405.
73. WHO Global Health Atlas. World Health Organization. Available: <http://apps.who.int/globalatlas/dataQuery/default.asp>. Accessed: 31 Jan 2012.
74. Mathew AA, Keeffe JE, Le Mesurier RT, Taylor HR (2009) Trachoma in the Pacific Islands: evidence from Trachoma Rapid Assessment. *Br J Ophthalmol* 93: 866–870.
75. Adams KS, Burgess JA, Dharmage SC, Taylor H (2010) Trachoma surveillance in Australia, 2009. A report by the Nation Trachoma Surveillance and Reporting Unit. *Commun Dis Intell* 34(4): 375–395.
76. Lansing VC, Mukesh BN, Keeffe JE, Taylor HR (2010) Trachoma control in two Central Australian Aboriginal communities: a case study. *Int Ophthalmol* 30: 367–375.
77. WHO (2010) Epidemiologic review of leprosy in the Western Pacific Region, 2008–2010: sustaining leprosy services and further reducing the leprosy burden. World Health Organization Western Pacific Region.
78. Lush D, Hargrave JC, Merianos A (1998) Leprosy control in the Northern Territory. *Australian and New Zealand Journal of Public Health* 22: 709–713.
79. Johnson PDR, Lavender CJ (2009) Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. *Emerging Infectious Diseases* 14: 614–615.
80. Lavender CJ, Fyfe JAM, Azoulas J, Brown K, Evans RN, et al. (2011) Risk of Buruli ulcer and detection of *Mycobacterium ulcerans* in mosquitoes in Southeastern Australia. *PLoS Negl Trop Dis* 5: e1305. doi:10.1371/journal.pntd.0001305
81. Dillon B, Valenzuela J, Don R, Blanckenberg D, et al. (2002) Limited diversity among human isolates of *Bartonella henselae*. *Journal of Clinical Microbiology* 40: 4691–499.
82. Flexman JP, Chen SC, Dickson DJ, Pearman JW, et al. (1997) Detection of antibodies to *Bartonella henselae* in clinically diagnosed cat scratch disease. *Med J Aust* 166: 532–535.
83. Zarkovic A, MacMurray C, Deva N, Ghosh S, et al. (2007) Seropositivity rates for *Bartonella henselae*, *Toxocara canis* and *Toxoplasma gondii* in New Zealand blood donors. *Clinical and Experimental Ophthalmology* 35: 131–134.
84. Guittet V, Menager C, Missotte I, Duparc B, et al. (2004) Hepatic abscesses in childhood: retrospective study about 33 cases observed in New-Caledonia between 1985 and 2003. *Arch Pediatr* 11: 1046–1053.
85. Baker MG, Lopez LD, Cannon MC, Lisle GWD, et al. (2006) Continuing *Mycobacterium bovis* transmission from animals to humans in New Zealand. *Epidemiol Infect* 134: 1068–1073.
86. Roche P, Bastian I, Krause V, Antic R, Brown L, et al. (2007) Tuberculosis notifications in Australia, 2005. *Commun Dis Intell* 31(1): 71–80.
87. NNDSS Annual Report Writing Group (2011) Australia's notifiable disease status, 2009: annual report of the national notifiable diseases surveillance system. *Commun Dis Intell* 35(2): 61–131. Available: [http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3502-pdf-cnt.htm/\\$FILE/cdi3502a.pdf](http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3502-pdf-cnt.htm/$FILE/cdi3502a.pdf). Accessed 5 Jan. 2013.
88. Tulsiani SM, Lau CL, Graham GC, Van Den Hurk AF, et al. (2010) Emerging tropical diseases in Australia. Part 1. Leptospirosis. *Annals of Tropical Medicine and Parasitology* 104: 543–556.
89. Institute of Environmental Science and Research Limited (2010) Notifiable and other diseases in New Zealand: Annual Report. pp. 23–51.
90. Thornley CN, Baker MG, Weinstein P, Maas EW (2002) Changing epidemiology of human leptospirosis in New Zealand. *Epidemiol Infect* 128: 29–36.
91. Goarant C, Laumond-Barny S, Perez J, Vernel-Paulillac F, et al. (2009) Outbreak of leptospirosis in New Caledonia: diagnosis issues and burden of disease. *Trop Med Int Health* 14(8): 926–929.
92. Lau CL, Dobson AJ, Smythe LD, Fearnley EJ, et al. (2012) Leptospirosis in American Samoa 2010: epidemiology, environmental drivers, and the management of emergence. *Am J Trop Med Hyg* 86: 309–319.
93. Berlioz-Arthaud A, Kiedrzyński T, Singh N, Yvon JF, et al. (2007) Multicentre survey of incidence and public health impact of leptospirosis in the Western Pacific. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 101: 714–721.
94. Coudert C, Beau F, Berlioz-Arthaud A, Melix G, et al. (2007) Human leptospirosis in French Polynesia. Epidemiological, clinical and bacteriological features. *Med Trop (Mars)* 67: 137–144.
95. Rosewell A, Dagina R, Murhekar M, Ropa B, et al. (2011) Vibrio cholera O1 in 2 Coastal Villages, Papua New Guinea. *Emerging Infectious Diseases* 17: 154–156.
96. World Health Organization Global Task Force on Cholera Control (2010) Cholera country profile: Papua New Guinea. 14 July; 1–2.
97. Nair GB, Safa A, Bhuiyan NA, Nusrin S, et al. (2006) Isolation of *Vibrio cholera* O1 strains similar to pre-seventh pandemic El Tor strains during an outbreak of gastrointestinal disease in an island resort in Fiji. *Journal of Medical Microbiology* 55: 1559–1562.
98. Hare FE (1898) The 1897 epidemic of dengue in North Queensland. *Australas Med Gaz* 17: 98–107.
99. Kiedrzyński T, Soures Y, Stewart T (1998) Dengue in the Pacific: an updated story. *Pacific Health Dialog* 5: 129–136.
100. Arima Y, Matsui T (2011) Epidemiologic update of dengue in the Western Pacific Region, 2010. *Western Pacific Surveillance and Response* 2(2): 1–5.
101. Van Den Hurk AF, Craig SB, Tulsiani SM, Jansen CC (2010) Emerging tropical diseases in Australia. Part 4. Mosquito-borne diseases. *Annals of Tropical Medicine and Parasitology* 104: 623–640.
102. Darcy A, Clothier H, Phillips D, Bakote'e B, Stewart T (2001) Solomon Islands dengue seroprevalence study—previous circulation of dengue confirmed. *PNG Med J* 44: 43–47.
103. Senn N, Luang-Suarkia D, Manong D, Siba PM, et al. (2011) Contribution of dengue fever to the burden of acute febrile illnesses in Papua New Guinea: an age-specific prospective study. *Am J Trop Med Hyg* 85: 132–137.
104. Anga G, Barnabas R, Kaminiel O, Tefuarani N, Vince J, Ripa P, Riddell M, Duke T (2010) The aetiology, clinical presentations and outcome of febrile encephalopathy in children in Papua New Guinea. *Ann Trop Paediatr* 30(2): 109–118.
105. Hanna JN, Ritchie SA, Phillips DA, Shield J, et al. (1996) An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. *Medical Journal Australia* 165: 256–260.
106. Johansen CA, van den Hurk AF, Ritchie SA, Zborowski P, et al. (2000) Isolation of Japanese encephalitis virus from mosquitoes (Diptera: Culicidae) collected in the Western Province of Papua New Guinea, 1997–1998. *J Trop Med Hyg* 62(5): 631–638.
107. Bennett NM, Moran R (2009) Peculiarities of Murray Valley encephalitis (MVE) epidemics in south-eastern Australia: the Indian Ocean dipole (IOD) as a predictor of epidemics. *Victorian Infectious Diseases Bulletin* Dec; 12:112–5.
108. Kelly-Hope LA, Purdie DM, Kay BH (2004) Ross River virus disease in Australia, 1886–1998, with analysis of risk factors associated with outbreaks. *J Med Entomol* 41: 133–150.
109. Hii J, Dyke T, Dagoro H, Sanders RC (1997) Health impact assessments of malaria and Ross River virus infection in the Southern Highlands Province of Papua New Guinea. *P N G Med J* 40: 14–25.
110. Klapsing P, MacLean JD, Glaze S, McClean KL, et al. (2005) Ross River virus disease reemergence, Fiji, 2003–2004. *Emerg Infect Dis* 11: 613–615.
111. Fitzsimmons GJ, Wright P, Johansen CA, Whelan PI, et al. (2009). Arboviral diseases and malaria in Australia, 2007/2008: annual report of the National Arbovirus and Malaria Advisory Committee. *Commun Dis Intell* 33: 155–169.
112. Clucas DB, Carville KS, Connors C, Currie PJ, et al. (2011) Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. *Bulletin of the World Health Organization*. 4(86).
113. Carapetis JR, Connors CM, Yarmirr D, Krause V, et al. (1997) Success of scabies control program in an Australian Aboriginal community. *Pediatric Infectious Disease Journal* 16(5): 494–499.
114. Holt DC, McCarthy JS, Carapetis JR (2010) Parasitic diseases of remote Indigenous communities in Australia. *International Journal for Parasitology* 40: 1119–1126.
115. Brockarie MJ, Alexander NDE, Kazura JW, Bockarie F, et al. (2000) Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. *Acta Tropica* 75: 127–130.

116. Lawrence G, Leafasia J, Sheridan J, Hills S, et al. (2005) Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. *Bulletin of the World Health Organization* January 83: 34–40.
117. Steer AC, Jenney AW, Kado J, Batzloff MR, et al. (2009) High burden of impetigo and scabies in a tropical country. *PLoS Negl Trop Dis* 3: e467. doi: 10.1371/journal.pntd.0000467
118. Thomas M (2005) Soil-transmitted helminth infection, skin infection, anaemia, and growth retardation in schoolchildren of Taveuni Island, Fiji. *N Z Med J* 118: 50–61.
119. Brooks PA, Grace RF (2002) Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. *J Paediatr Child Health* 38: 401–404.
120. Derraik JGB, Heath ACG, Rademaker M (2010) Human myiasis in New Zealand: imported and indigenously-acquired cases; the species of concern and clinical aspects. *N Z Med J* 123: 21–27.
121. World Health Organization (2012) Lymphatic filariasis fact sheet N°102. Available: <http://www.who.int/mediacentre/factsheets/fs102/en/>. Accessed 31 Dec. 2012.
122. Webber RH (1977) The natural decline of *Wuchereria bancrofti* infection in a vector control situation in the Solomon Islands. *Trans R Soc Trop Med Hyg* 71: 396–400.
123. Government of New Zealand (2012) Population with low incomes - social report 2010.
124. Fiji Islands Bureau of Statistics (2010) Fiji facts and figures as at 1st July 2010. Available: <http://www.statsfiji.gov.fj/releases/FFF2010.pdf>. Accessed 20 Jan. 2012.
125. Solomon Islands National Statistics Office and UNDP Pacific Centre Suva (2008) Solomon Islands analysis of the 2005/06 household income and expenditure survey. 1–56.
126. World Health Organization Western Pacific Region (2011) French Polynesia progress towards the health MDGs World Health Organization. Western Pacific country health information profiles 2010 revision. Geneva: WHO. pp. 110–122. Available: <http://www.wpro.who.int/publications/CHIPS2010.pdf>. Accessed 5 Jan. 2013.
127. Secretariat of the Pacific Community, Institute of Statistics and Economic Studies, New Caledonia (2010) Regional meeting of heads of statistics and planning. Statistics 2020: developing sustainable national and regional statistical capacities. New Caledonia. Available: http://www.spc.int/sdp/index.php?option=com_docman. Accessed 6 Feb. 2012.
128. Prime Minister's Office, Government of the Republic of Vanuatu (2010) Millennium Development Goals 2010 report for Vanuatu. Available: http://planipolis.iiep.unesco.org/upload/Vanuatu/Vanuatu_MDG_2010_eng.pdf. Accessed 1 Feb. 2012.
129. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, et al. (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. *Lancet* 367(9521): 1521–1532.
130. WHO (2010) Global Programme to Eliminate Lymphatic Filariasis progress report 2008–2009 and strategic plan 2010–2020. Geneva: WHO.
131. Hughes RG (2004) Environmental influences on helminthiasis and nutritional status among Pacific schoolchildren. *International Journal of Environmental Health* 14(3): 163–177.
132. Bockarie MJ (2000) Towards eliminating lymphatic filariasis in Papua New Guinea: impact of annual single-dose mass treatment on transmission of *Wuchereria Bancrofti* in East Sepik Province. *The Papua New Guinea Medical Journal* 43(3–4): 172–182.
133. Fraser M (2005) Evaluation of the Programme to Eliminate Lymphatic Filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. *The American Journal of Tropical Medicine and Hygiene* 73(4): 753–758.
134. Esterre P (2005) The history of Lymphatic Filariasis Control Programme in French Polynesia: lessons from a 50 years effort. *Bulletin De La Société De Pathologie Exotique Et De Ses Filiales* 98.1: 41–50.
135. Macnish MG, Ryan UM, Behnke JM, Thompson RC (2003) Detection of the rodent tapeworm *Rodentolepis* (= *Hymenolepis*) *microstoma* in humans. A new zoonosis? *Int J Parasitol* 33(10): 1079–1085.
136. Michel CC, Roper KG, Divina MA, Lee HH, et al. (2011) Correlation of clinical trachoma and infection in Aboriginal communities. *PLoS Negl Trop Dis* 5: e986. doi:10.1371/journal.pntd.0000986
137. Slack AT, Symonds ML, Dohnt MF, Smythe LD (2006) The epidemiology of leptospirosis and the emergence of *Leptospira borgpetersenii* serovar *Arborea* in Queensland, Australia, 1998–2004. *Epidemiol Infect* 134: 1217–1225.
138. Benschop J, Heuer C, Jaros P, Collins-Emerson J, Midwinter A, Wilson P (2009) Sero-prevalence of leptospirosis in workers at a New Zealand slaughterhouse. *N Z Med J* 122(1307): 39–47.
139. Beriloz-Arthaud A, Mérien F, Baranton G (2007) Laboratory based human leptospirosis surveillance in New Caledonia (2001–2005). *Bull Soc Pathol Exot* 100: 133–138.
140. Morann O, Queyrel V (2003) Leptospirosis in Espiritu Santo, Vanuatu, 8 case reports. *Med Trop (Mars)* 63: 611–613.
141. Hoque ME (2002) *Giardia* infection in Auckland and New Zealand: trends and international comparison. *N Z Med J* 115: 121–123.
142. Manning LA, Ogle GD (2002) Yaws in the periurban settlements of Port Moresby, Papua New Guinea. *PNG Med J* 45(3–4): 206–212.
143. Sullivan EA, Abel M, Tabrizi S, Garland SM, et al. (2003) Prevalence of sexually transmitted infections among antenatal women in Vanuatu, 1999–2000. *Sex Transm Dis* 30: 362–366.
144. Hewagama S, Einsiedel L, Spelman T (2011) *Staphylococcus aureus* bacteraemia at Alice Springs Hospital, Central Australia, 2003–2006. *Intern Med J* 42: 505–512.
145. Andrews RM, Kearns T, Connors C, Parker C, et al. (2009) A regional initiative to reduce skin infections amongst Aboriginal children living in remote communities of the Northern Territory, Australia. *PLoS Negl Trop Dis* 3: e554. doi: 10.1371/journal.pntd.0000554